Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Fulcrum Therapeutics, Inc is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 73 staff and has a trailing 12-month revenue of around USD$2.8 million.
|Latest market close||USD$12.04|
|52-week range||USD$5.32 - USD$22.96|
|50-day moving average||USD$8.4779|
|200-day moving average||USD$13.5273|
|Wall St. target price||USD$17.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-50.401|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-24)||12.73%|
|1 month (2020-10-30)||22.11%|
|3 months (2020-09-01)||66.07%|
|6 months (2020-06-01)||-36.53%|
|1 year (2019-11-29)||-2.51%|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Revenue TTM||USD$2.8 million|
|Gross profit TTM||USD$0|
|Return on assets TTM||-40.6%|
|Return on equity TTM||-76.09%|
|Market capitalisation||USD$300.1 million|
TTM: trailing 12 months
There are currently 1.1 million Fulcrum Therapeutics shares held short by investors – that's known as Fulcrum Therapeutics's "short interest". This figure is 34.2% up from 854,243 last month.
There are a few different ways that this level of interest in shorting Fulcrum Therapeutics shares can be evaluated.
Fulcrum Therapeutics's "short interest ratio" (SIR) is the quantity of Fulcrum Therapeutics shares currently shorted divided by the average quantity of Fulcrum Therapeutics shares traded daily (recently around 228850.89820359). Fulcrum Therapeutics's SIR currently stands at 5.01. In other words for every 100,000 Fulcrum Therapeutics shares traded daily on the market, roughly 5010 shares are currently held short.
However Fulcrum Therapeutics's short interest can also be evaluated against the total number of Fulcrum Therapeutics shares, or, against the total number of tradable Fulcrum Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fulcrum Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Fulcrum Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0628% of the tradable shares (for every 100,000 tradable Fulcrum Therapeutics shares, roughly 63 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Fulcrum Therapeutics.
Find out more about how you can short Fulcrum Therapeutics stock.
We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.